ImmuneOnco Biopharmaceuticals (Shanghai) (HKG:1541) has completed the placement of 33,150,000 shares to at least six investors at HK$7.05 apiece to raise net proceeds of HK$229.7 million, a Thursday bourse filing said.
The shares represent around 8.14% of the pharmaceutical company's enlarged issued share capital.
The company will use proceeds from the placement to fund clinical studies of different drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments